Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Ziopharm Oncology is raising $19,515,153.00 in a new round of investment. Sources indicate as part of senior management President, David Mauney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ziopharm Oncology

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.

To learn more about Ziopharm Oncology, visit http://www.ziopharm.com/

Contact:
David Mauney, President
617-259-1970
dmauney@ziopharm.com
https://www.linkedin.com/in/david-mauney-b72925168/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved